Study Overview

The table below provides an overview on the cohort studies included in Adata(Viewer). It displays the number of recruited participants and key information on the respective study design. Additionally, links are provided which facilitate access to the underlying datasets.


Legend

Cohort Participants Healthy MCI Patients AD Patients 2+ visits Follow-up Interval Location Diagnostic Criteria Reference Data Access
A4 6943 6943 0 0 0* ~8 USA, Canada, Australia Amyloid positive, cog. healthy DOI https://ida.loni.usc.edu/login.jsp
ADNI 2249 813 1016 389 1978 6 USA, Canada NINCDS-ADRDA DOI http://adni.loni.usc.edu/data-samples/access-data
AIBL 1378 803 134 181 1019 18 Australia NINCDS-ADRDA DOI Shared through consortium
ANMerge 1702 793 397 512 1254 12 Europe NINCDS-ADRDA DOI https://www.synapse.org/#!Synapse:syn4988768
EMIF 1221 386 526 201 0 no follow-up Europe NINCDS-ADRDA DOI Shared through consortium
JADNI 537 151 233 149 518 6 Japan NINCDS-ADRDA DOI https://humandbs.biosciencedbc.jp/en/hum0043-v1
EPAD 1500 1410 80 3 0* 6 Europe NINCDS-ADRDA DOI http://ep-ad.org/erap/
NACC 40858 15894 3649 11761 27657 12 USA UDS Form D1 DOI https://www.alz.washington.edu/
ROSMAP 3627 2514 898 203 3335 12 USA NINCDS-ADRDA DOI https://www.radc.rush.edu/

Demographics and Alzheimer's Disease Biomarkers

The table below summarizes the demographic characteristics of each cohort and describes the distributions of important Alzheimer’s disease biomarkers at study baseline. Distributions of demographic and biomarker values are described using the 25, 50 and 75% quantiles of the raw measured values. To make absolute values of biomarker measures more comparable, we additionally report the deviation between the healthy control group of one respective cohort and a selected participant subgroup of the same study (i.e. all, healthy, MCI and AD). This deviation is given as the quantiles received when evaluating the raw value quantiles under the empirical cumulative distribution function (ECDF) of the control group of the respective cohort.


Legend


Female % Age Education APOE4 % MMSE CDR CDRSB Hippocampus A-beta tTau pTau
A4 57.7 68, 71, 75 14, 16, 18 34.3 28, 29, 30 0.0, 0.0, 0.0 0.0, 0.0, 0.0 6, 7, 7 (25, 50, 75) NaN NaN NaN
ADNI 47.0 68, 73, 78 14, 16, 18 45.6 26, 28, 29 0.0, 0.5, 0.5 0.0, 1.0, 2.0 5948, 6864, 7651 (7, 26, 60) 596, 854, 1396 (12, 27, 57) 193, 258, 350 (36, 66, 88) 17, 24, 34 (37, 69, 91)
AIBL 57.9 67, 73, 79 10, 12, 15 36.0 26, 28, 30 0.0, 0.0, 0.5 0.0, 0.0, 1.0 3, 3, 3 (11, 37, 71) 445, 567, 802 (nan) 238, 366, 516 (nan) 43, 64, 81 (nan)
ANMerge 59.3 71, 77, 81 8, 11, 14 38.8 24, 28, 29 0.0, 0.5, 0.5 0.0, 0.5, 4.0 5311, 6270, 7142 (2, 20, 54) NaN NaN NaN
EMIF 46.2 62, 68, 74 9, 12, 15 46.8 25, 28, 29 0.5, 0.5, 0.5 NaN 6357, 7223, 8004 (5, 27, 62) 385, 525, 739 (10, 36, 65) 160, 278, 504 (35, 73, 96) 37, 52, 74 (38, 72, 94)
EPAD 56.9 60, 66, 71 12, 15, 17 37.7 28, 29, 30 0.0, 0.0, 0.0 0.0, 0.0, 0.0 4413, 4808, 5182 (24, 49, 74) 899, 1319, 1700 (24, 50, 100) 162, 201, 252 (26, 51, 76) 13, 17, 22 (26, 51, 76)
JADNI 52.7 66, 72, 77 12, 12, 16 46.1 24, 26, 29 0.0, 0.5, 0.5 0.0, 1.5, 3.0 5260, 6133, 7132 (1, 7, 40) 254, 315, 454 (7, 13, 46) 67, 101, 138 (59, 89, 96) 36, 48, 73 (59, 89, 96)
NACC 57.2 65, 72, 79 12, 16, 18 40.6 23, 27, 29 0.0, 0.5, 0.5 0.0, 1.0, 4.0 43.5% 46.5% 43.9% 43.9%
ROSMAP 72.8 73, 79, 84 14, 16, 18 25.1 27, 29, 30 NaN NaN NaN NaN NaN NaN